<DOC>
	<DOC>NCT00599287</DOC>
	<brief_summary>The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium, severity of delirium, length of ICU/hospital stay and side effects between the different interventions.</brief_summary>
	<brief_title>Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients</brief_title>
	<detailed_description />
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Older than 18 years Diagnosed as hypoactive delirium Informed consent given Pregnancy Epilepsy M. Parkinson Lewybody dementia Prolonged QTtime Known allergy to the medicinals used Renal replacement therapy Hepatic encephalopathy Hyperthyroid Glaucoma Previous suicide attempts Syndrome of Gilles de la Tourette Patients which cannot receive the medication oral or through a nasogastric tube</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>ICU delirium</keyword>
	<keyword>Hypoactive delirium</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>Hypoactive ICU delirium</keyword>
</DOC>